Product Description
Mechanisms of Action: ADRB3 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Overactive Bladder
Phase 1: Healthy Volunteers|Spinal Cord Injuries
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT02256735 | P1 |
Completed |
Healthy Volunteers |
2005-12-01 |
|
NCT02256722 | P1 |
Completed |
Healthy Volunteers |
2005-11-01 |
|
2004-004590-28 | P2 |
Completed |
Overactive Bladder |
2005-06-30 |
|
NCT02259751 | P1 |
Completed |
Spinal Cord Injuries |
2005-02-01 |